ATE328874T1 - Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren - Google Patents

Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren

Info

Publication number
ATE328874T1
ATE328874T1 AT01998116T AT01998116T ATE328874T1 AT E328874 T1 ATE328874 T1 AT E328874T1 AT 01998116 T AT01998116 T AT 01998116T AT 01998116 T AT01998116 T AT 01998116T AT E328874 T1 ATE328874 T1 AT E328874T1
Authority
AT
Austria
Prior art keywords
derivatives
triazolediamine
substituted
kinase inhibitors
kinase
Prior art date
Application number
AT01998116T
Other languages
English (en)
Inventor
Ronghui Lin
Peter J Connolly
Steven Wetter
Shenlin Huang
Stuart Emanual
Robert Guninger
Steve Middleton
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE328874T1 publication Critical patent/ATE328874T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01998116T 2000-12-22 2001-12-21 Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren ATE328874T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25770300P 2000-12-22 2000-12-22

Publications (1)

Publication Number Publication Date
ATE328874T1 true ATE328874T1 (de) 2006-06-15

Family

ID=22977396

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01998116T ATE328874T1 (de) 2000-12-22 2001-12-21 Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren

Country Status (23)

Country Link
US (2) US6924302B2 (de)
EP (1) EP1355889B1 (de)
CN (1) CN100357278C (de)
AT (1) ATE328874T1 (de)
BG (2) BG107959A (de)
BR (1) BR0116792A (de)
CA (1) CA2432870A1 (de)
CZ (1) CZ20031941A3 (de)
DE (1) DE60120494T2 (de)
DK (1) DK1355889T3 (de)
ES (1) ES2266313T3 (de)
HU (1) HUP0303868A3 (de)
IL (1) IL156584A0 (de)
MX (1) MXPA03005777A (de)
NO (1) NO20032848L (de)
NZ (1) NZ526624A (de)
PL (1) PL363316A1 (de)
PT (1) PT1355889E (de)
RU (1) RU2274639C2 (de)
SK (1) SK9062003A3 (de)
WO (1) WO2002057240A1 (de)
YU (1) YU51803A (de)
ZA (1) ZA200305619B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060293256A1 (en) * 2002-08-06 2006-12-28 Masateru Yamada Remedy or preventive for kidney disease and method of diagnosing kidney disease
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
BRPI0410331A (pt) 2003-05-13 2006-05-30 Depuy Spine Inc método para tratar doença de disco degenerativa
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US7553827B2 (en) 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US8361467B2 (en) 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
WO2005013982A1 (en) * 2003-08-06 2005-02-17 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
DE10356579A1 (de) * 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
WO2005070042A2 (en) * 2004-01-09 2005-08-04 Smithkline Beecham Corporation Novel chemical compounds
ATE481134T1 (de) 2004-01-21 2010-10-15 Univ Emory Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
EP1720843A2 (de) * 2004-02-11 2006-11-15 Janssen Pharmaceutica N.V. Verfahren zur herstellung substituierter triazolverbindungen
WO2006042215A1 (en) * 2004-10-08 2006-04-20 Janssen Pharmaceutica, N.V. 1,2,4-triazolylaminoaryl (heteroaryl) sulfonamide derivatives
SI1811998T1 (sl) 2004-10-21 2011-01-31 Vertex Pharma Triazoli uporabni kot inhibitorji proteinskih kinaz
DE102004055998A1 (de) 2004-11-19 2006-05-24 Rheinische Friedrich-Wilhelms-Universität Bonn Niedermolekulare Inhibitoren von Guaninnucleotid-Austauschfaktoren der Cytohesin-Familie
MX2007008781A (es) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
WO2007030680A2 (en) * 2005-09-07 2007-03-15 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as axl inhibitors
US7879887B2 (en) 2006-06-29 2011-02-01 Nissan Chemical Industries, Ltd. α-amino acid derivatives and medicaments containing the same as an active ingredient
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
DE102006054205A1 (de) * 2006-11-15 2008-05-29 Rheinische Friedrich-Wilhelms Universität Verwendung von Cytohesin-Inhibitoren zur chemischen Induktion von Langlebigkeit
CA2695613A1 (en) 2006-12-19 2008-06-26 Pharmos Corporation Sulfonamide derivatives with therapeutic indications
ES2672172T3 (es) * 2006-12-29 2018-06-12 Rigel Pharmaceuticals, Inc. Triazoles N3-heteroarilsustituidos y triazoles N5-heteroarilsustituidos útiles como inhibidores de Axl
EP2078010B1 (de) 2006-12-29 2014-01-29 Rigel Pharmaceuticals, Inc. Als axl-inhibitoren geeignete polycyclische heteroarylsubstituierte triazole
EP2114955B1 (de) 2006-12-29 2013-02-13 Rigel Pharmaceuticals, Inc. Durch verbrücktes bicyclisches aryl bzw. verbrücktes bicyclisches heteroaryl substituierte triazole, die sich als axl-inhibitoren eignen
EP2079736B1 (de) 2006-12-29 2017-10-18 Rigel Pharmaceuticals, Inc. Substituierte triazole als axl-hemmer
WO2008083353A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
JP2011500625A (ja) 2007-10-18 2011-01-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ トリ置換された１，２，４−トリアゾール
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
WO2009054864A1 (en) 2007-10-26 2009-04-30 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
MX2010008700A (es) 2008-02-22 2010-08-30 Hoffmann La Roche Moduladores de beta-amiloide.
AR070936A1 (es) 2008-03-19 2010-05-12 Janssen Pharmaceutica Nv 1,2,4 -triazoles trisustituidos
JP5486591B2 (ja) 2008-05-09 2014-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アセチルコリン受容体モジュレーターとしての三置換ピラゾール
US8431594B2 (en) 2008-07-09 2013-04-30 Rigel Pharmaceuticals, Inc. Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors
CA2730231C (en) 2008-07-09 2016-10-18 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
ES2429517T3 (es) 2008-10-09 2013-11-15 F. Hoffmann-La Roche Ag Moduladores para la beta amiloide
CN102209537A (zh) 2008-11-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 杂环γ分泌酶调节剂
SG172997A1 (en) * 2009-01-16 2011-08-29 Rigel Pharmaceuticals Inc Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US20140010783A1 (en) * 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
CA2890002A1 (en) * 2012-11-05 2014-05-08 Nant Holdings Ip, Llc Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway
CA2900892A1 (en) * 2013-03-05 2014-09-12 F. Hoffmann-La Roche Ag Antiviral compounds
KR20150126901A (ko) * 2013-03-06 2015-11-13 에프. 호프만-라 로슈 아게 항바이러스성 화합물
WO2018175670A1 (en) 2017-03-22 2018-09-27 The Research Foundation For The State University Of New York Matrix metalloproteinase-9 hemopexin domain inhibitors and methods of treatment using same
US12110278B2 (en) * 2020-10-13 2024-10-08 Yale University Selective JAK2 pseudokinase ligands and methods of use
CN118475583A (zh) * 2021-10-26 2024-08-09 瓦索卡地亚公司 Gpr39蛋白的拮抗剂
CN114292243B (zh) * 2022-01-12 2023-11-21 中山大学 一种三唑类衍生物或其药学上可接受的盐及其制备方法和应用
CN115433222A (zh) * 2022-09-20 2022-12-06 五邑大学 一种2-(偕二氟丙烯)苯甲酰胺类化合物的制备方法及其应用
WO2026006527A1 (en) * 2024-06-26 2026-01-02 The Board Of Trustees Of The Leland Stanford Junior University Covalent inhibitors of jak2 jh2 domain

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2352944A (en) * 1942-07-04 1944-07-04 Gen Electric Triazole derivatives
NL301383A (de) * 1962-12-06
US4727022A (en) * 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US5196351A (en) * 1987-09-30 1993-03-23 Beckman Instruments, Inc. Bidentate conjugate and method of use thereof
HU206095B (en) * 1989-10-25 1992-08-28 Egyt Gyogyszervegyeszeti Gyar Process for producing triazolylcarboxylc acid hydrazie and semicarbazide derivatives and pharmaceutical compositions comprising same
HU206096B (en) * 1989-11-24 1992-08-28 Egyt Gyogyszervegyeszeti Gyar Process for producing triazolylcarboxylic acid thioamide derivatives and pharmaceutical compositions comprising same
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
DK0580737T3 (da) * 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
TW225526B (de) * 1991-09-02 1994-06-21 Yamanouchi Pharma Co Ltd
US5543507A (en) * 1992-03-05 1996-08-06 Isis Pharmaceuticals, Inc. Covalently cross-linked oligonucleotides
US5362859A (en) * 1992-07-27 1994-11-08 Sepracor, Inc. High-capacity affinity supports and methods for the preparation and use of same
US5512435A (en) * 1993-02-05 1996-04-30 Renschler; Markus F. Receptor-binding antiproliferative peptides
WO1995003286A1 (en) 1993-07-23 1995-02-02 The Green Cross Corporation Triazole derivative and pharmaceutical use thereof
US5698401A (en) * 1995-11-14 1997-12-16 Abbott Laboratories Use of nuclear magnetic resonance to identify ligands to target biomolecules
NZ503788A (en) * 1997-10-27 2002-11-26 Agouron Pharma 4-aminothiazole derivatives and their use as inhibitors of cyclin-dependent kinases
GB9918180D0 (en) * 1999-08-02 1999-10-06 Smithkline Beecham Plc Novel compositions

Also Published As

Publication number Publication date
WO2002057240A1 (en) 2002-07-25
CN100357278C (zh) 2007-12-26
CA2432870A1 (en) 2002-07-25
NO20032848L (no) 2003-08-20
US20050182116A1 (en) 2005-08-18
EP1355889A1 (de) 2003-10-29
PT1355889E (pt) 2006-09-29
BG107959A (bg) 2004-12-30
MXPA03005777A (es) 2005-02-14
IL156584A0 (en) 2004-01-04
NZ526624A (en) 2005-07-29
BR0116792A (pt) 2004-02-17
NO20032848D0 (no) 2003-06-20
US6924302B2 (en) 2005-08-02
BG107985A (bg) 2004-11-30
PL363316A1 (en) 2004-11-15
US7317031B2 (en) 2008-01-08
RU2003118448A (ru) 2005-01-27
EP1355889B1 (de) 2006-06-07
HUP0303868A2 (hu) 2004-03-01
DE60120494T2 (de) 2006-12-21
RU2274639C2 (ru) 2006-04-20
SK9062003A3 (en) 2004-04-06
HUP0303868A3 (en) 2008-03-28
CN1575284A (zh) 2005-02-02
DE60120494D1 (de) 2006-07-20
ZA200305619B (en) 2004-10-21
DK1355889T3 (da) 2006-10-09
CZ20031941A3 (cs) 2004-08-18
US20040077699A1 (en) 2004-04-22
ES2266313T3 (es) 2007-03-01
YU51803A (sh) 2006-05-25
HK1057373A1 (en) 2004-04-02

Similar Documents

Publication Publication Date Title
ATE328874T1 (de) Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren
CY1117951T1 (el) Αναστολεiς κινασης υποκατεστημενης τριαζινης
AP1718A (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
ID27838A (id) Inhibitor 1,2,3,4-tetrahidrokinolin tersubstitusi 2-tersubstitusi 4-amino sebagai inhibitor cetp
PT1202724E (pt) Metodo para tratamento da dor cronica utilizando inibidores mek
MXPA03008485A (es) Derivados espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7.
PT1446387E (pt) Derivados de aril-1,4-pirazina substituídos
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
ATE316785T1 (de) Jak-3 hemmer zur behandlung von allergischen störungen
DE69828682D1 (de) Nanomolare, non-peptidische inhibitoren von cathepsin d
ATE289598T1 (de) Glutamin-thiazolidide und -pyrrolidide sowie ihre verwendung als dipeptidylpeptidase iv inhibitoren
DE60130555D1 (de) 1-(heteroaryl-phenyl)-kondensierte pyrazol-derivate als factor xa inhibitoren
IL139080A0 (en) Btx inhibitors and methods for their indentification and use
MXPA03008690A (es) Inhibidores novedosos de tirosina cinasa.
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
DE60020595D1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
DE60216278D1 (de) Polyoxyalkylen-ammoniumsalze und ihre verwendung als antistatika
EA200400235A1 (ru) Комбинированная терапия для лечения рака
NO20015062L (no) Substituerte 3-cyano-[1.7],[1.5]og[1.8]-naftyridin- inhibitorer for tyrosin-kinaser
IS6914A (is) 2-þíó-útskiptar imídasólafleiður og notkun þeirraí lyfjaiðnaðinum
IL152097A0 (en) Use of pyrazole derivatives for treating infertility
ATE281439T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
MXPA03001484A (es) Quinazolinas, medicamentos que contienen estos compuestos, y son efectivos como inhbidores de tirosina quinasa, su utilizacion y metodos para su produccion.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1355889

Country of ref document: EP